How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about neratinib

Marketing authorisation indication

Neratinib (Nerlynx, Pierre Fabre) is indicated for the extended adjuvant treatment of adults with early stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who are less than 1 year from the completion of prior adjuvant trastuzumab-based therapy.

Dosage in the marketing authorisation

Neratinib is administered orally. The recommended dose is 240 mg neratinib, administered as 6 × 40 mg tablets taken once daily and continually for 1 year.

Price

£4,500 per box of 180 tablets (30 days treatment) (excluding VAT; company's submission).

The company has a commercial arrangement (simple discount patient access scheme). This makes neratinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.